Welcome to the Desert Angels™. We are a Tucson, Arizona based non-profit organization of accredited investors who seek opportunities to invest in Southwest regional startup or early stage companies. The organization serves as a forum for its over 90 members, who invest individually from their personal funds. Since 2000, Desert Angel members have invested over $37 million in more than 85 presenting companies.

Tempronics Successfully Closes $9.5M Series C Round

by Curtis Gunn on September 13th, 2016 at 4:36pm

Lear Corporation Leads Round and Enters into a Strategic Partnership to Bring a New Generation of Heating and Cooling Technology to the Automotive Market

Tempronics, a thermoelectric company with proprietary new technology in solid state heating and cooling, is partnering with the Lear Corporation (NYSE: LEA), a leading global supplier of automotive seating and electrical systems, to provide a new generation of thermal comfort to the automotive seating market. Other investors include Nth Power, the Desert Angels, management and individual investors.

Read full article here

Comment

Lear Enters into a Strategic Partnership with Tempronics and Secures Exclusive Rights to Thermoelectric Seat Heating and Cooling Technology for use in Automotive Applications

by Curtis Gunn on September 8th, 2016 at 4:26pm

Lear Corporation (NYSE: LEA), a leading global supplier of automotive seating and electrical systems, today announced that it has entered into a strategic partnership with Tempronics, pursuant to which Lear obtained a minority equity interest in Tempronics and also secured exclusive rights to its thermoelectric seat heating and cooling technology for automotive applications.

“This partnership will provide Lear with the ability to heat and cool seats faster utilizing less energy than any other system available today,” said Ray Scott, Lear’s executive vice president and president of Seating.

Read full article here

Comment

FDA Allows NuvOx Pharma’s IND to Initiate Phase Ib Clinical Trial in Stroke.

by Curtis Gunn on August 19th, 2016 at 5:06pm

Evan Unger, MD, President and CEO of NuvOx, announced that the FDA has allowed an investigational new drug application (IND) for NVX-208 (dodecafluoropentane emulsion) to be tested in a Phase Ib trial in stroke patients.

The trial will be performed at the University of Arkansas Medical System in Little Rock, Arkansas under the direction of Dr. William Culp, Jonathan Fitch Distinguished Chair in Stroke. Dr. Culp said, “We have studied NVX-208 in a number of pre-clinical stroke models and found that administration of NVX-208 decreases the brain damage from stroke by over 80%. The only approved drug to treat stroke is t-PA, which has a risk of bleeding and is approved for use only up to 3 hours following stroke. Administration of NVX-208 prior to t-PA extended the time window of efficacy to at least 9-hours. NVX-208 has great potential to allow many more stroke patients to be treated and to improve their outcomes. This trial will determine the recommended dose of NVX-208 in stroke patients so that it can be subsequently tested in a randomized study in stroke patients.”

Read full article here

Comment

Filed under: Funded Companies, Press

PR Product Recommendation: IrisPR Software

by Curtis Gunn on August 11th, 2016 at 5:05pm

We recently started using the new PR performance software tool IrisPR and we are loving it!

You can tell IrisPR is a tool created by PR professionals. With it, you can capture the names of your media contacts, gather the clips of the coverage you generate, and track the status of your PR campaigns and pitches! It’s as if your media database merged with your media monitoring service and all those spreadsheets of PR results that you’ve had to create yourself!

Read full article here

Comment

Filed under: Funded Companies, Press

Man lives 555 days without a heart

by Curtis Gunn on June 21st, 2016 at 7:04pm

“It feels like a real heart”

It’s not the first time a patient has lived for a long time with an artificial heart, but Larkin became the first patient in Michigan to go home with the portable device.

The SynCardia temporary artificial heart in Larkin’s chest replaced his failing heart, including its chambers and four valves. Two tubes, exiting the left side of Stan’s body beneath the ribcage, connected the artificial heart to a 13-pound machine called the Freedom Driver.

Read the full article here

Comment

Filed under: Funded Companies, Press

Top Companies: Best small companies to work for in Arizona

by Curtis Gunn on June 13th, 2016 at 5:04pm

Portfolio companies, Picmonic and Regenesis Biomedical, make Arizona best small company list.

Read full article here

Comment

Filed under: Funded Companies, Press

‘Huntsman’ tie-in a hit for Tucson game studio

by Curtis Gunn on June 4th, 2016 at 8:33pm

Tucson-based video game development studio Desert Owl Games continues to grow, with the launch of a “Huntsman” movie tie-in game, the 10-year anniversary of its biggest title and upcoming work with Sony.

Read full article here

Comment

Filed under: Funded Companies, Press

ReplyBuy Nominated for Best in Mobile Fan Experience, Further Solidifying Its Market Presence

by Curtis Gunn on April 27th, 2016 at 5:45pm

ReplyBuy, the global sales platform that combines mobile messaging, payments and digital commerce, continues to experience rapid growth within its initial launch market. Sports and entertainment are the company’s first industry verticals. Over the past year, there has been a significant increase in the number of organizations that have embraced ReplyBuy to power instant mobile sales by removing the friction that typically accompanies event-related consumer transactions. In addition to public-facing exposure, the company is also experiencing notoriety among peers and industry authorities.

ReplyBuy was recently honored for its innovative solution and proven results with some significant award nominations. The company was nominated in the category of “Best in Mobile Fan Experience” for the 2016 Sports Business Awards, hosted by the Sports Business Journal. Nominees were announced on March 14 and winners will be announced on May 18 in New York City at the New York Marriott Marquis at Times Square. This nomination is especially significant to ReplyBuy because of the vast number of sports teams that trust its solution to help them engage with their fans

Click here for full article

Comment

Filed under: Funded Companies, Press

HTG Molecular Diagnostics Expands Distribution into Israel, Spain and Portugal

by Curtis Gunn on April 20th, 2016 at 8:18pm

HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), (“HTG”), a provider of instruments and reagents for molecular profiling applications, today announced distribution agreements with Gamidor Diagnostics (“Gamidor”) in Israel and Durviz s.l. Parque Tecnológico de Valencia (“Durviz”) in Spain and Portugal to manage distribution of HTG’s next generation sequencing (NGS)-based products.

Click here for full article

Comment

Filed under: Funded Companies, Press

Clinical Trial Evaluating CPP-1X/sulindac in Patients with Familial Adenomatous Polyposis

by Curtis Gunn on April 4th, 2016 at 7:38pm

Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today that target enrollment has been achieved for the company’s pivotal Phase 3 clinical trial, CPP FAP-310, evaluating CPP-1X/sulindac in adults with familial adenomatous polyposis (FAP). FAP is a rare genetic disease that, if untreated, progresses to colorectal cancer in almost all cases. The trial has enrolled 166 patients at 21 research institutes in the United States, Canada and Europe.

Click here for full article

Comment

Filed under: Funded Companies, Press